Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Genetic polymorphism of CYP2D6 in a keralite (South India) population.

Literature DB >> 10718787

Genetic polymorphism of CYP2D6 in a keralite (South India) population.

B K Abraham, C Adithan, C H Shashindran, S Vasu, N A Alekutty.

Abstract

Entities: Gene

Mesh：

Substances：
Cytochrome P-450 CYP2D6

Year: 2000 PMID： 10718787 PMCID： PMC2014911 DOI： 10.1046/j.1365-2125.2000.00142-2.x

Source DB: PubMed Journal: Br J Clin Pharmacol ISSN： 0306-5251 Impact factor: 4.335

× No keyword cloud information.

12 in total

1. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

Authors: Y C Lou; L Ying; L Bertilsson; F Sjöqvist
Journal: Lancet Date: 1987-10-10 Impact factor: 79.321

2. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.

Authors: M V Relling; J Cherrie; M J Schell; W P Petros; W H Meyer; W E Evans
Journal: Clin Pharmacol Ther Date: 1991-09 Impact factor: 6.875

3. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

Authors: K Nakamura; F Goto; W A Ray; C B McAllister; E Jacqz; G R Wilkinson; R A Branch
Journal: Clin Pharmacol Ther Date: 1985-10 Impact factor: 6.875

4. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

Authors: B Schmid; J Bircher; R Preisig; A Küpfer
Journal: Clin Pharmacol Ther Date: 1985-12 Impact factor: 6.875

5. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

Authors: K Weerasuriya; R L Jayakody; C A Smith; C R Wolf; G T Tucker; M S Lennard
Journal: Br J Clin Pharmacol Date: 1994-11 Impact factor: 4.335

6. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.

Authors: C Funck-Brentano; G Thomas; E Jacqz-Aigrain; J M Poirier; T Simon; G Béréziat; P Jaillon
Journal: J Pharmacol Exp Ther Date: 1992-11 Impact factor: 4.030

7. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

Authors: Y Horai; M Nakano; T Ishizaki; K Ishikawa; H H Zhou; B I Zhou; C L Liao; L M Zhang
Journal: Clin Pharmacol Ther Date: 1989-08 Impact factor: 6.875

Genetic polymorphism of CYP2D6 in a keralite (South India) population.

1. Low frequency of slow debrisoquine hydroxylation in a native Chinese population.

2. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects.

3. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations.

4. Polymorphic dextromethorphan metabolism: co-segregation of oxidative O-demethylation with debrisoquin hydroxylation.

5. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study.

6. Polymorphism of dextromethorphan metabolism: relationships between phenotype, genotype and response to the administration of encainide in humans.

7. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.

8. Genetic polymorphism of CYP2D6 in North Indian subjects.

9. The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population.

10. Determination of dextromethorphan and its O-demethylated metabolite from urine.

1. Genetic polymorphism of CYP2D6 in Tamil population.

2. Evaluation of cytochrome P450 2D6 phenotyping in healthy adult Western Indians.

3. Cytochrome P₄₅₀ 2D6 polymorphism in eastern Indian population.